Recursion prices $200M public offering of 30.8M shares at $6.50 per share

RECURSION PHARMACEUTICALS, INC.

Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
Offering comprises 30,769,230 shares of Class A common stock at $6.50 per share.
Underwriters granted 30-day option to purchase up to additional 4,615,384 shares.
Expected closing date June 28, 2024, subject to customary conditions.
Goldman Sachs & Co. LLC and J.P. Morgan are lead book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.